Keylynk 7339-008
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study’s 2 primary hypotheses are:
Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to progression-free survival (PFS) per RECIST 1.1 by blinded independent clinical review (BICR).
Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to overall survival (OS).
CLINICALTRIALS.GOV IDENTIFIER:
NCT03976362
When speaking to your doctor, please have the trial identifier number available.
All patients who enroll in the trial will receive medication while on the study. All patients will receive induction therapy pembrolizumab plus carboplatin and either paclitaxel or nab-paclitaxel.
50% of those randomized to maintenance therapy will receive pembrolizumab along with olaparib if the patient is still eligible after induction therapy
50% of those randomized to maintenance therapy will receive pembrolizumab along with placebo if the patient meets the criteria after induction therapy
Tests the medicine or vaccine in approximately 1,000 to 5,000 volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices.
Dates
Conditions
Carcinoma, Squamous Cell, Non-small-cell Lung
Age Range
18 - No Age Maximum
Sex
All
If you think this trial might be a fit and are interested in participating, take the next step to see if you are eligible.
Print this page or email it to your doctor to discuss at your next visit.
CLINICALTRIALS.GOV IDENTIFIER:
NCT03976362
When speaking to your doctor, please have the trial identifier number available.
Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.
Print this page
Email this page